We hereby give notice that the Annual Meeting of Stockholders of Spine Injury Solutions, Inc. (formerly Spine Pain Management, Inc.) will be held on June 28, 2012,November 10, 2015, at 4:2:00 p.m. local time, at 5225 Katy Freeway, Suite 600, Houston, Texas 77007, for the following purposes:

Under Delaware law, only stockholders of record on the record date, which is May 18, 2012,September 24, 2015, are entitled to notice of and to vote at the Annual Meeting or any adjournment. It is important that your shares of common stock be represented at this meeting so that the presence of a quorum is assured.

Your vote is important. Even if you plan to attend the meeting in person, please date and execute the enclosed proxy and return it promptly in the enclosed postage-paid envelope as soon as possible. If you attend the meeting, you may revoke your proxy and vote your shares in person.

Under the rules of the New York Stock Exchange (“NYSE”), brokers who hold shares in “street name” for customers are precluded from exercising voting discretion with respect to the approval of non-routine matters (so called “broker non-votes”) where the beneficial owner has not given voting instructions. Effective July 1, 2009, the NYSE amended its rule regarding discretionary voting by brokers on uncontested elections of directors such that any investor who does not instruct the investor’s broker on how to vote in an election of directors will cause the broker to be unable to vote that investor’s shares on an election of directors. Previously, the broker could exercise its own discretion in determining how to vote the investor’s shares even when the investor did not instruct the broker on how to vote. Accordingly, withWith respect to the election of directors (see Proposal(Proposal 1), a broker is not entitled to vote the shares of common stock unless the beneficial owner has given instructions. With respect to the ratification of the appointmentselection of Ham, Langston & Brezina, LLP as our independent registered public accounting firm (see Proposal(Proposal 2), a broker will have discretionary authority to vote the shares of common stock if the beneficial owner has not given instructions.

Under our bylaws, the Board of Directors consists of at least one director and may consist of such number of directors as may be fixed from time to time by action of the stockholders or of the Board of Directors.  Directors are elected to hold office until the next annual meetingAnnual Meeting of stockholdersStockholders and until their successors are elected and qualified or until their earlier resignation or removal.  As of the date hereof,Presently, the Board of Directors consists of five members.members, William F. Donovan, M.D., John Bergeron, Jerry Bratton, Peter L. Dalrymple and Franklin A. Rose, M.D.  Our Board of Directors has approveddid not nominate Franklin A. Rose for re-election to the increase in the numberBoard.

Our Board of members of the Board from five to six, and hasDirectors approved and recommendedrecommends to stockholders the election of sixfive nominees to serve on the Board.  These nominees are William F. Donovan, M.D., John A. Talamas, John Bergeron, Jerry Bratton, FranklinPeter L. Dalrymple and Jeffrey A. Rose, M.D. and William Lawrence. FiveCronk, D.C.  Four of the nominees including William F. Donovan, M.D., John A. Talamas, John Bergeron, Jerry Bratton and Franklin A. Rose, M.D., presently serve as members of our Board of Directors, including Dr. Donovan, Mr. Bergeron, Mr. Bratton and are accordingly standing for re-election. The remaining nominee, William Lawrence,Mr. Dalrymple.  Dr. Cronk currently holds no positionpositions with us.the company.  There are no family relationships among any of our directors, director nominees or executive officers.

The persons named in the enclosed Proxy (“Proxy”) have each been selected by the Board of Directors to serve as proxy and will vote the shares represented by valid proxies at the Annual Meeting and adjournments thereof.  Unless otherwise instructed or unless authority to vote is withheld, the enclosed Proxy will be voted for the election of the nominees listed below.  Each duly elected director will hold office until his successor shall have been elected and qualified.  Although our Board of Directors does not contemplate that any of the nominees will be unable to serve, if such a situation arises prior to the Annual Meeting, the person named in the enclosed Proxy will vote for the election of such other person(s) as may be nominated by the Board of Directors.

The names of the nominees for election to the Board, their principal occupations and certain other information follow:

Executive officers are appointed to serve at the discretion of the Board.  Our current executive officers are as follows:

See “Information Regarding Nominees” above for biographical information of Dr. Donovan and Mr. Bergeron.

Eric K. Groteke, D.C. – age 40 – In May 2012, Dr. Groteke was appointed as our Chief Technology Officer and Senior VP of Sales/Marketing position. He has owned and operating outpatient clinics in Florida from May 2005 through present day as a managing partner and Chiropractic Physician. He was co-founder and co-developer of MSDR, a musculoskeletal health risk assessment tool, while he authored an IRB approved research study on The Quantification and Tracking of Osteoarthritis that was published in the March/April Issue of The Journal of Medicine in 2009. During this time he served as an adjunct professor at NY Chiropractic College in their Research Department and collaborated with Georgetown University Medical Center, Department of Anesthesia to make this research study possible. In September 2009, Dr. Groteke presented this research at the National PAINWeek Conference in Las Vegas, Nevada. In July 2008, Dr. Groteke was awarded a patent on a cervical orthopedic device that supports the head and neck, and he has several other patents that are currently pending in medical algorithms and other types of medical devices. In addition to the above, he was runner up for the Tampa Bay healthcare hero award in 2009 for Innovation and Research. Dr. Groteke graduated from New York Chiropractic College in 1996, then went in private practice in Pennsylvania, where he owned and operated multidisciplinary group practices from 1997 to 2005.

In September 2010, Dr. Groteke was forced to file Chapter 7 bankruptcy due to business debt that he personally guaranteed. The bankruptcy occurred after Dr. Groteke and his partners could not reach an amicable resolution. The bankruptcy has been discharged.

All directors are expected to make every effort to attend meetings of the Board, meetings of any Board Committees on which such director serves, and annual meetings of stockholders.  The Board of Directors held five meetings during the fiscal year ended December 31, 2011.2014.  The Board of Directors also executed one consent to action in lieu of a meeting of the Board of Directors, which was approved unanimously. We currently havehas an Audit Committee, a Compensation Committee and a Nominating Committee.  During 2011,2014, the Audit Committee held fourthree meetings, the Compensation Committee held one meeting, and the Nominating Committee held one meeting.  Also during 2014, the independent members of the Board of Directors held one “executive session” meeting.  Of our currentincumbent directors, during 2011, none2014 only Franklin A. Rose, M.D. attended fewer than 75 percent of the aggregate of (i) the total number of meetings of the Board of Directors (including consents to action in lieu of a meeting) held during the period for which he has been a director, and (ii) the total number of meetings held by all committees of the Board on which he served during the periods that he served.

  Four directors attended the 2014 Annual Meeting of Stockholders.

Any stockholder desiring to contact the Board, or any specific director(s), may send written communications to: Board of Directors (Attention: (Name(s) of director(s), as applicable)), c/o President, 5225 Katy Freeway, Suite 600, Houston, Texas 77007.  Any communication so received will be processed and conveyed to the member(s) of the Board named in the communication or to the Board, as appropriate, except for junk mail, mass mailings, product or service complaints or inquiries, job inquiries, surveys, business solicitations or advertisements, or patently offensive or otherwise inappropriate material.

We currently have two independent directors on our Board, Jerry Bratton, J.D. and Franklin A. Rose, M.D.  Dr. Rose is not standing for reelection at the 2015 Annual Meeting.  Additionally, William Lawrence, whoa director nominee, Jeffrey A. Cronk, D.C., J.D., is a nominee for election to the Board, is deemed independent.  The definition of “independent” used herein is arbitrarily based on the independence standards of The NASDAQ Stock Market LLC.  The Board performed a review to determine the independence of Franklin A. Rose, M.D., Jerry Bratton and William LawrenceJeffrey Cronk and made a subjective determination as to each of these directors and/or nominees that no transactions, relationships or arrangements exist that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director of Spine Pain Management,Injury Solutions, Inc.  In making these determinations, the Board reviewed information provided by these individualsdirectors with regard to each’seach individual’s business and personal activities as they may relate to us and our management.

Our Board is currently composed of five directors, with William F. Donovan, M.D. carrying the title of “Chairman” of the Board.  In addition to serving on the Board, Dr. Donovan also currently serves as President and Chief Executive Officer.  Accordingly, there is often little separation in Dr. Donovan’s role as principal executive officer and his role as Chairman.  To mitigate any apparent conflicts this Board leadership structure may create, we previously maintainedhave chosen to maintain a Board of Directors consisting of a majority ofthat includes independent directors.  In September 2011, however, we appointed oneCurrently two of our five directors are independent, and if all five nominees are elected at the 2015 Annual Meeting, two of five of our directors John Bergeron, as Chief Financial Officer. This appointment made Mr. Bergeron no longer an independent director, reducing the number of independent directors from three to two. We have, however, nominated William Lawrence for election to the Board, and we anticipate appointing an additional independent director in the near future.will be independent.  We believe maintaining a majority of independent directors allows the Board to better oversee and manage risk.  None of our independent directors holdholds the title of “lead” independent director.  Accordingly, all of our independent directors have an equal role in the leadership of the Board.  We believe that our overall leadership structure is appropriate based on our current size.

As a part of its oversight function, the Board of Directors monitors how management operates the company.  Risk is an important part of deliberations at the Board and committee level throughout the year.  Committees consider risks associated with their particular areas of responsibility.  The Board of Directors as a whole considers risks affecting us.  The Board and its committees consider, among other things, the relevant risks to the company when granting authority to management and approving business strategies. Through this risk oversight process, the Board reserves the right to make changes to our leadership structure in the future if it deems such changes are appropriate and in the best interest of our stockholders.

We maintain a separately-designated standing audit committee.  The Audit Committee currently consists of Peter Dalrymple and our two independent directors, Jerry Bratton and Franklin Rose, M.D.  Mr. Bratton is the Chairman of the Audit Committee, and the Board of Directors has determined that he is an audit committee financial expert as defined in Item 5(d)(5) of Regulation S-K. The primary purpose of the Audit Committee is to oversee our accounting and financial reporting processes and audits of our financial statements on behalf of the Board of Directors.  The Audit Committee meets privately with our management and with our independent registered public accounting firm and evaluates the responses by our management both to the facts presented and to the judgments made by our outside independent registered public accounting firm.  Our Audit Committee has reviewed and discussed our audited financial statements for the year ended December 31, 20102014 with our management.

In January 2011, our Board adopted a charter for the Audit Committee.  A copy of the Charter of the Audit Committee can be found in our website at www.spinepaininc.com/investor-information.www.spinepaininc.com.  The Charter establishes the independence of our Audit Committee and sets forth the scope of the Audit Committee's duties.  A majority of the members of the Audit Committee will be independent.  The Audit Committee is objective, and reviews and assesses the work of our independent registered public accounting firm and our internal accounting.

The Audit Committee has reviewed and discussed with management the audited financial statements of Spine Pain Management,Injury Solutions, Inc. for the fiscal year ended December 31, 2011.2014.  The Audit Committee has discussed with Ham, Langston & Brezina, LLP, our independent auditors (“HLB”), the matters required to be discussed by the statement on Auditing Standards No. 61, as amended (AICPA, Professional Standards, Vol. 1, AU section 380), as adopted by the Public Company Accounting Oversight Board in Rule 3200T.  The Audit Committee has received the written disclosures and the letter from HLB required by applicable requirements of the Public Company Accounting Oversight Board regarding HLB’s communications with the Audit Committee concerning independence, and has discussed with HLB the independence of HLB.

Based on the review and discussions referred to in the paragraph above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our annual report on Form 10-K for the fiscal year ended December 31, 2011.2014.  This report is furnished by the Audit Committee of our Board of Directors, whose members are:

All information within this “Audit Committee” section of the Proxy Statement, including but not limited to the Report of the Audit Committee, shall not be deemed to be “soliciting material,” or to be “filed” with the SEC or subject to Regulation 14A or 14C (17 CFR 240.14a-1 through 240.14b-2 or 240.14c-1 through 240.14c-101) or to the liabilities of section 18 of the Exchange Act.  Such information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

We have a Compensation Committee whose members are Jerry Bratton, Peter Dalrymple and Franklin Rose, M.D.  Our Compensation Committee does not currently have a written charter.  Our Compensation Committee makes recommendations to the Board of Directors as to employee benefit programs and officer, director and employee compensation.  The primary objectives of our executive compensation programs are to: (1) attract, retain and motivate skilled and knowledgeable individuals; (2) ensure that compensation is aligned with our corporate strategies and business objectives; (3) promote the achievement of key strategic and financial performance measures by linking short-term and long-term cash  and equity incentives to the achievement of measurable corporate and individual performance goals; and (4) align executives’ and directors’ incentives with the creation of stockholder value.  To achieve these objectives, our Compensation Committee evaluates our executive compensation program with the objective of setting compensation at levels it believes will allow us to attract and retain qualified executives and directors.  The Compensation Committee will take under consideration recommendations from executive officers and directors regarding its executive compensation program.  The Compensation Committee also has the authority to obtain advice and assistance from external advisors, including compensation consultants, although the Compensation Committee did not elect to retain a compensation consultant to assist with determining executive compensation during 2011.

2014.

We have a Nominating Committee whose members are Jerry Bratton, Peter Dalrymple and Franklin Rose, M.D.  The Nominating Committee’s primary duties are to indentify,identify, evaluate and recommend to the Board nominees for director.  See “Procedures for Director Nominations” below for the criteria it uses to evaluate nominee candidates. Based on our size, the Nominating Committee does not yet have a written charter and does not have a written policy with regard to the consideration of any director candidates recommended by stockholders.  The Nominating Committee will, however, consider written nominations of candidates for election to the Board properly submitted by stockholders. For information regarding the procedures for stockholder nominations to the Board, see “Procedures for Director Nominations” below.

Members of the Board are expected to collectively possess a broad range of skills, industry and other knowledge and expertise, and business and other experience useful for the effective oversight of our business.  All candidates must meet the minimum qualifications and other criteria established from time to time by the Board and the Nominating Committee.  In considering possible candidates for election as director, the Board and Nominating Committee are guided by the following standards:

We also consider the following criteria, among others, in our selection of directors:

The Nominating Committee evaluates suggestions concerning possible candidates for election to the Board submitted to us, including those submitted by Board members (including self-nominations) and stockholders. All candidates, including those submitted by stockholders, will be similarly evaluated by the Nominating Committee using the Board membership criteria described above and in accordance with applicable procedures, including such procedures prescribed by the SEC. Once candidates have been identified, the Nominating Committee will determine whether such candidates meet our qualifications for director nominees and select and recommend nominees to the Board accordingly.

As noted above, the Nominating Committee will consider qualified director nominees recommended by stockholders when such recommendations are submitted in accordance with applicable SEC requirements and any other applicable law, rule or regulation regarding director nominations. When submitting a nomination to us for consideration, a stockholder must provide certain information that would be required under applicable SEC rules, including the following minimum information for each director nominee: full name and address; age; principal occupation during the past five years; current directorships on publicly held companies and registered investment companies; and number of shares of our common stock owned, if any.  No candidates for director nominations were submitted to the Board by any stockholder in connection with the 20122014 Annual Meeting.

The following table provides summary information for the years 20112014 and 20102013 concerning cash and non-cash compensation paid or accrued to or on behalf of certain executive officers:

officers (“named executive officers”).

On FebruarySeptember 16, 2012,2014, we entered into an employment agreement with our President and Chief Executive Officer, William F. Donovan, M.D.   On February 20, 2012, the agreement was amended to eliminate certain stock award provisions. The employment agreement, as amended, (i) terminates and supersedes the previous employment agreement that we entered into with Dr. Donovan on or about May 17, 2010, which was to expire on in May 2012 unless earlier terminated, (ii) has a term that ends on March 31, 2014, and (iii)contract provides that we will pay Dr. Donovan an annual base salary of $96,000.$120,000. The agreement also provides that we may grant Dr. Donovan performance bonuses from time to time at the discretion of the Board of Directors.  The agreement has a confidentiality provision and provides that Dr. Donovan cannot compete with us for a period upon termination of Dr. Donovan’s May 2010the agreement.

Mr. Bergeron’s employment agreement accordingly terminated his right under that agreement to receive 1,000,000 restricted shares of common stock if he is employed by us on June 30 of the calendar year in which we achieve an annual fully diluted earnings per share of at least $0.01 as reflected in the audited financial statements filed with an annual report on Form 10-K filed with the SEC.

In May 2010, we entered into an employment agreement with our then Chief Operating Officer, John A. Talamas.  Pursuant to the employment agreement, which had a term thatcontract expired on May 1, 2012, we issued Mr. Talamas 50,000 shares of restricted common stock as consideration for his new employment.  The agreement also provided that we may grant Mr. Talamas performance bonuses from time to time at the discretion of the Board of Directors. Additionally, the employment agreement provided that we will transfer to Mr. Talamas 500,000 restricted shares of common stock if Mr. Talamas is employed by us under his employment agreement on JuneNovember 30, of the calendar year in which we achieve an annual fully diluted earnings per share of at least $0.01 as reflected in the audited financial statements filed with an annual report on Form 10-K filed with the SEC. After discussions with management, however, on February 26, 2012 Mr. Talamas confirmed in writing that he was waiving his right to receive these 500,000 shares. After the expiration of his employment agreement, Mr. Talamas stepped down as Chief Operating Officer on May 9, 2012 but has continued to serve as one of our Directors.

In September 2011, we entered into an employment agreement with our Chief Financial Officer, John Bergeron. The employment agreement’s term began on October 1, 2011 and will expire on September 30, 2012. The agreement provides that Mr. Bergeron receive an annual base salary of $51,000 and a signing bonus of 100,000 shares of restricted common stock as consideration for his new employment. The agreement also provides that we may grant Mr. Bergeron performance bonuses from time to time at the discretion of the Board of Directors.

2014. 

The following table details all outstanding equity awards held by our named executive officers at December 31, 2011:

		Option Awards
Name		Number of Securities Underlying Unexercised Options (#) Exercisable				Number of Securities Underlying Unexercised Options (#) Unexercisable				Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)				Option Exercise Price ($)				Option Expiration Date
William F. Donovan, M.D.			50,000	(1)			500,000				-				0.77				6/6/2016
John A. Talamas			25,000	(2)			250,000				-				0.77				6/6/2016

2014:

We attempt to make our compensation programs discretionary, balanced and focused on the long term.  We believe goals and objectives of our compensation programs reflect a balanced mix of quantitative and qualitative performance measures to avoid excessive weight on a single performance measure. Our approach to compensation practices and policies applicable to employees and consultants is consistent with that followed for its executives.  Based on these factors, we believe that our compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on us.

Section 16(a) of the Securities Exchange Act of 1934 requires our directors and executive officers, and persons who own beneficially more than ten percent of our common stock, to file reports of ownership and changes of ownership with the Securities and Exchange Commission. Based solely upon a review of Forms 3, 4 and 5 furnished to us we are aware of five people who, during the fiscal year ended December 31, 20112014, we believe that the directors, executive officers, and greater than ten percent beneficial owners have complied with all applicable filing requirements during the fiscal year ended December 31, 2014, except for (i) a Form 4 that was filed late by William Donovan, our Chief Executive Officer, (ii) a Form 3 and two Form 4s that were Directors, officers, orfiled late by Peter Dalrymple, a Director, and (iii) a Form 3 and Form 4 that were filed late by LPD Investments, Ltd, a beneficial ownersowner of more than ten percent10% of our common stock over which Mr. Dalrymple has voting and who failed to file, on a timely basis, reports required by Section 16(a) of the Securities Exchange Act of 1934, as follows:

John Bergeron, our Chief Financial Officer and Director, failed to timely file a Form 4 in connection with our issuance to him of stock options on June 6, 2011.  He ultimately filed this report, however, on June 20, 2011.

Jerry Bratton, our Director, failed to timely file a Form 4 in connection with our issuance to him of stock options on June 6, 2011.  He ultimately filed this report, however, on June 20, 2011.

William Donovan, M.D., our Chief Executive Officer and Director, failed to timely file a Form 4 in connection with our issuance to him of stock options on June 6, 2011.  He ultimately filed this report, however, on June 17, 2011.

Franklin Rose, M.D., our Director, failed to timely file a Form 4 in connection with our issuance to him of stock options on June 6, 2011. He ultimately filed this report, however, on June 20, 2011.

John Talamas, our Director and former Chief Operating Officer, failed to timely file a Form 4 in connection with our issuance to him of stock options on June 6, 2011. He ultimately filed this report, however, on June 20, 2011.

investment authority.

We have an agreement with Northshore Orthopedics, Assoc. ("NSO"), which is 100% owned by our Chief Executive Officer, William Donovan, M.D., to provide medical services as our independent contractor. Under the agreement, we incurred $635,700 worth of debt during the year ended December 31, 2011, against which we paid NSO $211,000 during the year. As of December 31, 20112013 and 2010,2012, we had balances payable to NSO of $1,020,200$0 and $740,500,$10,406, respectively. This outstanding payable is non-interest bearing, due on demand and does not follow any specific repayment schedule. We do not directly pay Dr. Donovan (in his individual capacity as a physician) any fees in connection with NSO. However, Dr. Donovan is the sole owner of NSO, and we pay NSO under the terms of our agreement. During the year ended December 31, 2010, we issued 285,714 shares of common stock to Dr. Donovan for the conversion of $200,000 of outstanding debt owed by us to NSO. There were no shares issued for conversion of outstanding debt during the twelve months ended December 31, 2011. In February 2012, however, NSO agreed to convert into common stock $1,020,200 of outstanding debt at the price of $1.83 per share, which was the closing market price on Friday, February 17, 2012. This resulted in us issuing to NSO 557,486 restricted shares of common stock on February 28, 2012.

Additionally, as shown in Note 56 of the accompanying financial statements, in our Form 10-K for the year endedat December 31, 2011, at both December 31, 20112014 and 2010,2013, we had a balancebalances of $310,699$0 and $135,699, respectively, due to Dr. Donovan, in his individual capacity, for working capital advances and payments made on behalf of us. This outstanding payable is non-interest bearing, due on demand and does not follow any specific repayment schedule.

We

On August 20, 2014, we entered into a Financing Agreement with Mr. Dalrymple whereby he agreed to assist us in obtaining financing in the form of a $2,000,000 revolving line of credit (see line of credit below) from a commercial lender and personally guaranty the line of credit. Under the terms of the Financing Agreement, upon finalization of the line of credit with Wells Fargo Bank on September 8, 2014, we (i) extended the term of the $1,000,000 promissory note by one year to mature on August 29, 2016, (ii) reduced the interest rate on the promissory note to 6%, (iii) extended the expiration date on the warrants issued in connection with a major stockholder (a beneficial ownerthe promissory note by one year to an expiration date of over 5%August 29, 2016 and (iv) used $500,000 of our common stock) on June 30, 2011. The note matures on June 30, 2013 and accrues interest atadvances under the rateline of 6% per annum. Allcredit as payment of principal and accrued but unpaid interest is payable in one paymenton the promissory note.

Additionally, as consideration for agreeing to extend the promissory note and reduce the interest rate, we issued to Mr. Dalrymple 200,000 unvested and restricted shares of common stock, which stock vested upon maturityfinalization of the line of credit with Wells Fargo Bank on June 30, 2013. At December 31, 2011, the related party receivable was $163,703. There was no note receivable at December 31, 2010.

We have had anSeptember 8, 2014.

On September 3, 2014, we entered into a $2,000,000 revolving line of credit agreement with Wellness WoRx Center, PLLC ("WWC"), whichWells Fargo Bank that is 100% ownedpersonally guaranteed by our Senior VPMr. Dalrymple. Under the terms of Salesthe financing agreement previously discussed, we granted 800,000 unvested and Marketing/Chief Technology Officer, Eric Groteke, D.C.,restricted shares of common stock to provide medical servicesMr. Dalrymple with 100,000 shares vesting upon finalization of the line of credit agreement on September 8, 2014, and the remaining shares vesting, in 100,000 share increments, quarterly so long as our independent contractor at certain Florida centers. We pay WWC varying amounts per month under the agreement, which amounts averaged approximately $85,000 per month based on the year ended December 31, 2011.

revolving credit remains in effect.

The following table sets forth certain information, at May 18, 2012 with respect toas of September 24, 2015, concerning, except as indicated by the beneficial ownership of shares of common stock byfootnotes below, (i) each person known to us whowhom we know beneficially owns beneficially more than 5% of the outstanding shares ofour common stock, (based upon reports which have been filed and other information known to us), (ii) each of our Directorsdirectors, (iii) each of our Director nominees,named executive officers, (iv) all of our directors and executive officers as a group, and (v) each of our executive officersnominees for election to the Board of Directors.  We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and (v) all of our executive officers and Directors as a group.  Unless otherwise indicated, each stockholder hasentities named in the table below have sole voting and investment power with respect to the shares shown.  As of May 18, 2012, there were 17,815,882all shares of common stock outstanding.

Name and Address of Beneficial Owner		Number of Common Shares Beneficially Owned				Percent of Class
William F. Donovan, M.D. (1)			3,774,427	(2)			21.01	%
John A. Talamas (1)			600,000	(3)			3.35	%
Franklin A. Rose, M.D. (1)			175,000				0.98	%
John Bergeron (1)			175,000	(4)			0.98	%
Jerry Bratton (1)			1,581,100	(5)			8.86	%
Eric K. Groteke, D.C. (1)			85,000				0.48	%
All Directors and executive officers as a group (6 persons)			6,390,527				35.32	%
William A. Lawrence (6)			-				0	%
Rene Hamouth (7)			3,000,000				16.84	%

that they beneficially own, subject to applicable community property laws. Applicable percentage ownership is based on 19,755,882 shares of common stock outstanding at September 24, 2015. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to stock options or warrants held by that person that are currently exercisable or exercisable within 60 days of September 24, 2015. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise noted, stock options and warrants referenced in the footnotes below are currently fully vested and exercisable.

The following table summarizes our equity compensation plan information as of December 31, 2011:

Plan Category		(a) Common Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights				(b) Weighted-average Exercise Price of Outstanding Options, Warrants and Rights ($)				(c) Common Shares Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))
Equity compensation plans approved by our stockholders			--				--				--
Equity compensation plans not approved by our stockholders			875,000	(1)			0.77				--
Total			875,000				0.77				--